The Clinical Research Core will provide centralized, quality controlled services for specimen processing, regulatory protocol management, development of Standard Operating Procedures, and limited specialized assay testing to support the research of Projects 1,2,3 and 4. The core will be responsible for the identification, recruitment, and phlebotomy of individuals to support U19 research objectives as well as the regulatory oversight of IRB protocols related to U19 research. Through the efforts of research associates and technicians, the core will be responsible for the processing and storage of the blood and serum samples obtained. The core will be responsible for a Quality Control Materials program to provide services related to Quality assurance of reagents and assays used in U19 research. This would include the establishment and optimization of standardized protocols, the development of a centralized comprehensive repository of positive control cell lines, the establishment of subject registry related to immunological characteristics of interest and the performance of established T cell assays to determine antigen specificity of PBMC samples and reagents. In addition, the clinical research core will provide a limited number of HLA typings for each of the proposed U19 projects.
The scope of the research encompassed by the four U19 investigator-initiated projects and the Technology Development Project would benefit not only from the shared cost of the resources of the proposed clinical core but also from the structure to standardize and disseminate new technologies that are developed within the individual projects.
|Canetta, Sarah E; Bao, Yuanyuan; Co, Mary Dawn T et al. (2014) Serological documentation of maternal influenza exposure and bipolar disorder in adult offspring. Am J Psychiatry 171:557-63|
|Thompson, Mikayla R; Sharma, Shruti; Atianand, Maninjay et al. (2014) Interferon ?-inducible protein (IFI) 16 transcriptionally regulates type i interferons and other interferon-stimulated genes and controls the interferon response to both DNA and RNA viruses. J Biol Chem 289:23568-81|
|Mathew, Anuja; Townsley, Elizabeth; Ennis, Francis A (2014) Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections. Future Microbiol 9:411-25|
|Yin, Liusong; Trenh, Peter; Guce, Abigail et al. (2014) Susceptibility to HLA-DM protein is determined by a dynamic conformation of major histocompatibility complex class II molecule bound with peptide. J Biol Chem 289:23449-64|
|Parra, Miguel; Herrera, Daniel; Calvo-Calle, J Mauricio et al. (2014) Circulating human rotavirus specific CD4 T cells identified with a class II tetramer express the intestinal homing receptors ?4?7 and CCR9. Virology 452-453:191-201|
|Yin, Liusong; Stern, Lawrence J (2014) A novel method to measure HLA-DM-susceptibility of peptides bound to MHC class II molecules based on peptide binding competition assay and differential IC(50) determination. J Immunol Methods 406:21-33|
|Schmidt, Madelyn R; McGinnes-Cullen, Lori W; Kenward, Sarah A et al. (2014) Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory. J Virol 88:10165-76|
|Terajima, Masanori; Co, Mary Dawn T; Ennis, Francis A (2014) Age and different influenza viruses. Lancet Infect Dis 14:101|
|Outinen, T K; Mäkelä, S; Huttunen, R et al. (2014) Urine soluble urokinase-type plasminogen activator receptor levels correlate with proteinuria in Puumala hantavirus infection. J Intern Med 276:387-95|
|Co, Mary Dawn T; Terajima, Masanori; Thomas, Stephen J et al. (2014) Relationship of preexisting influenza hemagglutination inhibition, complement-dependent lytic, and antibody-dependent cellular cytotoxicity antibodies to the development of clinical illness in a prospective study of A(H1N1)pdm09 Influenza in children. Viral Immunol 27:375-82|
Showing the most recent 10 out of 78 publications